Claims for Patent: 9,669,136

Summary for Patent: 9,669,136

Title:	Tissue regeneration membrane
Abstract:	The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention.
Inventor(s):	Friedman; Michael (Jerusalem, IL), Sasson; Yoel (Rehovot, IL), Grin; Ada (Rehovot, IL), Mosheiff; Rami (Jerusalem, IL), Rachmilewitz; Jacob (Modi\'in, IL)
Assignee:	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (Jerusalem, IL) HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (Jerusalem, IL)
Application Number:	13/144,074
Patent Claims:	1. A sterile surgical implant for implantation within a subject, consisting of a homogenous membrane and, optionally, at least one type of cell, wherein said homogenous membrane comprises: at least one positively charged synthetic, hydrophobic polymer; at least one hydrophilic polymer, and at least one plasticizer, wherein said plasticizer is polyethylene glycol ranging from 300-20,000, and, optionally, at least one active agent. 2. A sterile surgical implant according to claim 1, wherein both said hydrophilic polymer and said plasticizer are polyethylene glycol ranging from 300-20,000. 3. A sterile surgical implant according to claim 2, wherein said at least one hydrophilic polymer is present in a concentration of between about 1% (w/w) to 30% (w/w) of the membrane. 4. A sterile surgical implant according to claim 1, wherein both said hydrophilic polymer and said plasticizer are polyethylene glycol 400. 5. A sterile surgical implant according to claim 4, wherein said polyethylene glycol 400 is present at a concentration of 5%, 10%, 15%, 20% or 25% w/w. 6. A sterile surgical implant according to claim 4, wherein said at least one hydrophilic polymer is present in a concentration of between about 1% (w/w) to 30% (w/w) of the membrane. 7. A sterile surgical implant according to claim 1, wherein said at least one hydrophilic polymer is present in a concentration of between about 1% (w/w) to 30% (w/w) of the membrane. 8. A sterile surgical implant according to claim 1, further consisting of at least one type of cell. 9. A sterile surgical membrane according to claim 8, wherein said cells are selected from the group consisting of adult stem cells, embryonic stem cells, pluripotent stem cells, mesenchymal stem cells, umbilical cord blood cells, osteoblasts, chondroblasts and CD105+ cells. 10. A sterile surgical implant according to claim 9, wherein said cells are autologous adult stem cells. 11. A sterile surgical implant according to claim 1, further consisting of at least one active agent, wherein said at least one active agent is selected from the group consisting of cytokine, hormone, bisphosphonate, cannabinoid, beta blocker, bone inducing agent, growth factor, HMG-CoA reductase inhibitor, drug and antibiotic. 12. A sterile surgical implant according to claim 11, wherein said active agent is selected from the group consisting of statin, estrogen, androgen, propranolol, transforming growth factor (TGF), bone morphogenetic protein (BMP), insulin like growth hormone, fibroblast growth factor (FGF), alendronate, risedronate and parathyroid hormone. 13. A sterile surgical implant according to claim 12, wherein said active agent is simvastatin or lovastatin. 14. A sterile surgical implant according to claim 1, wherein said membrane becomes porous upon hydration, and wherein the pore size is between about 0.1 to about 5 microns. 15. A sterile surgical implant according to claim 1, wherein said hydrophobic polymer is a methacrylate copolymer substituted by at least one amine group. 16. A sterile surgical implant according to claim 15, wherein said positively charged synthetic, hydrophobic polymer is ammonio methacrylate copolymer type A NF (AMCA). 17. A sterile surgical implant according to claim 1 which has a three dimensional shape formed without pre-casting, re-molding, or exposure to heat. 18. A sterile surgical implant according to claim 1 which has a three dimensional, hollow shape. 19. A sterile surgical implant according to claim 18 which has a three dimensional, hollow tubular shape. 20. A sterile surgical implant according to claim 1, wherein the membrane is hydrated upon implantation. 21. A sterile surgical implant according to claim 1, wherein said membrane has a thickness of between 30 and 200 m. 22. A sterile surgical implant according to claim 1, wherein said membrane has a thickness of 75, 87, 90, 104, 180 or 220 m. 23. A sterile surgical implant for implantation within a subject, consisting of a membrane and, optionally, at least one type of cell, wherein said membrane consists of: at least one positively charged synthetic, hydrophobic polymer; at least one hydrophilic polymer, and at least one plasticizer, wherein said plasticizer is polyethylene glycol ranging from 300-20,000. 24. A sterile surgical implant for implantation within a subject, consisting of a membrane and, optionally, at least one type of cell, wherein said membrane consists of: at least one positively charged synthetic, hydrophobic polymer; at least one hydrophilic polymer, at least one plasticizer, wherein said plasticizer is polyethylene glycol ranging from 300-20,000; and at least one active agent selected from the group consisting of cytokine, hormone, bisphosphonate, cannabinoid, beta blocker, bone morphogenetic protein (BMP), growth factor, HMG-CoA reductase inhibitor, antibiotic, statin estrogen, androgen, propranolol, transforming growth factor (TGF), insulin like growth hormone, fibroblast growth factor (FGF), alendronate, risedronate, parathvroid hormone, simvastatin, lovastatin, and combinations thereof. 25. A sterile surgical implant according to claim 24, wherein said active agent is selected from the group consisting of statin, estrogen, androgen, propranolol, transforming growth factor (TGF), bone morphogenetic protein (BMP), insulin like growth hormone, fibroblast growth factor (FGF), alendronate, risedronate, parathyroid hormone, and combinations thereof. 26. A sterile surgical implant according to claim 25, wherein said active agent is simvastatin or lovastatin.

Details for Patent 9,669,136

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2029-01-12